Spironolactone in Hidradenitis Suppurativa: A Single-Center Study

This study investigates the efficacy of spironolactone in treating hidradenitis suppurativa (HS) in women, particularly those of childbearing age. Conducted at a single center, the retrospective review included 53 female patients, with 84.1% showing improvement at 3 months and 81.8% at 6 months after starting spironolactone. The study found no significant differences in treatment response based on body mass index, menstrual HS flares, irregular menses, or polycystic ovarian syndrome. Adverse events were mild and infrequent. The study suggests spironolactone may be beneficial for female HS patients, but larger prospective studies are needed to better understand predictors of treatment response and optimal dosing.